Affinity Investment Advisors LLC decreased its stake in shares of Pfizer Inc. (NYSE:PFE) by 0.5% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 528,518 shares of the biopharmaceutical company’s stock after selling 2,426 shares during the period. Pfizer accounts for 2.2% of Affinity Investment Advisors LLC’s investment portfolio, making the stock its 6th biggest position. Affinity Investment Advisors LLC’s holdings in Pfizer were worth $18,868,000 as of its most recent filing with the SEC.
A number of other institutional investors also recently added to or reduced their stakes in the business. Miller Howard Investments Inc. NY lifted its stake in shares of Pfizer by 17.6% in the third quarter. Miller Howard Investments Inc. NY now owns 2,342,077 shares of the biopharmaceutical company’s stock worth $83,612,000 after acquiring an additional 351,008 shares in the last quarter. Essex Investment Management Co. LLC lifted its stake in shares of Pfizer by 16.5% in the third quarter. Essex Investment Management Co. LLC now owns 19,213 shares of the biopharmaceutical company’s stock worth $686,000 after acquiring an additional 2,720 shares in the last quarter. Canada Pension Plan Investment Board increased its holdings in Pfizer by 1.0% in the third quarter. Canada Pension Plan Investment Board now owns 10,818,226 shares of the biopharmaceutical company’s stock valued at $386,211,000 after buying an additional 104,600 shares during the last quarter. Longview Partners Guernsey LTD increased its holdings in Pfizer by 32.0% in the third quarter. Longview Partners Guernsey LTD now owns 24,369,672 shares of the biopharmaceutical company’s stock valued at $869,997,000 after buying an additional 5,901,100 shares during the last quarter. Finally, Brightworth bought a new stake in Pfizer in the third quarter valued at about $340,000. 69.74% of the stock is owned by institutional investors.
Several equities analysts have recently commented on PFE shares. Vetr lowered Pfizer from a “buy” rating to a “hold” rating and set a $35.71 target price for the company. in a report on Wednesday, September 13th. BMO Capital Markets reissued a “buy” rating and issued a $37.00 price objective on shares of Pfizer in a report on Thursday, September 14th. Jefferies Group set a $37.00 price objective on Pfizer and gave the stock a “neutral” rating in a report on Monday, September 18th. Sanford C. Bernstein set a $39.00 price objective on Pfizer and gave the stock a “buy” rating in a report on Tuesday, September 19th. Finally, Morgan Stanley raised Pfizer from an “equal weight” rating to an “overweight” rating and increased their price objective for the stock from $35.00 to $39.00 in a report on Wednesday, September 20th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and thirteen have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $38.83.
Shares of Pfizer Inc. (NYSE PFE) opened at $36.47 on Thursday. The firm has a market cap of $217,390.00, a PE ratio of 22.37, a P/E/G ratio of 2.46 and a beta of 1.01. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.43 and a quick ratio of 1.15. Pfizer Inc. has a one year low of $30.90 and a one year high of $37.35.
Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.02. The firm had revenue of $13.17 billion during the quarter, compared to analysts’ expectations of $13.17 billion. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. The company’s revenue for the quarter was up .9% compared to the same quarter last year. During the same quarter last year, the company earned $0.61 earnings per share. research analysts forecast that Pfizer Inc. will post 2.59 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 1st. Stockholders of record on Friday, February 2nd will be issued a dividend of $0.34 per share. This is a positive change from Pfizer’s previous quarterly dividend of $0.32. The ex-dividend date of this dividend is Thursday, February 1st. This represents a $1.36 annualized dividend and a dividend yield of 3.73%. Pfizer’s dividend payout ratio (DPR) is presently 78.53%.
Pfizer announced that its board has approved a stock repurchase plan on Monday, December 18th that authorizes the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization authorizes the biopharmaceutical company to purchase shares of its stock through open market purchases. Shares repurchase plans are generally a sign that the company’s management believes its stock is undervalued.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.